Jim Cramer Was Focused on These 13 Stocks Recently
“People keep asking me, why am I always urging traders to take profits in all these hyper speculative stocks, the ones that have had parabolic moves. The answer is simple.
Recursion Pharmaceuticals Inc. (RXRX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | ARK Investment Management Catherine D. Wood | 32,988,631 | $166,922,471 | -6% | 1.22% |
| 2. | MIC Capital Partners Mubadala Investment | 9,644,032 | $48,798,807 | 9.58% | |
| 3. | 1,715,562 | $8,680,744 | +362% | 0% | |
| 4. | 1,448,800 | $7,330,928 | +1938% | 0.01% | |
| 5. | Citadel Investment Group Ken Griffin | 1,314,552 | $6,651,633 | -51% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.82 | 66,822 | $522,354.26 | 12,985,927 | 2023-03-02 | Filing | |
| $7.94 | 48,867 | $388,082.17 | 12,919,105 | 2023-03-01 | Filing | |
| $7.97 | 815 | $6,495.55 | 12,870,238 | 2023-02-28 | Filing | |
| $7.69 | 52,500 | $403,725.00 | 12,869,423 | 2023-02-27 | Filing | |
| $7.64 | 109,118 | $833,552.40 | 12,816,923 | 2023-02-24 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.04 | 100,000 | $604,000.00 | 974,229 | 2025-10-10 | Filing | |
| $4.76 | 100,000 | $476,000.00 | 954,229 | 2025-09-25 | Filing | |
| $4.71 | 100,000 | $471,000.00 | 974,229 | 2025-09-10 | Filing | |
| $4.84 | 100,000 | $484,000.00 | 954,229 | 2025-08-26 | Filing | |
| $5.52 | 36,599 | $202,172.88 | 668,197 | 2025-08-18 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,630,000 | $7,954,400 | 0.16% | |
| 2. | 212,202 | $1,035,546 | 1% | |
| 3. | 143,164 | $698,530 | 0.01% | |
| 4. | 89,500 | $436,760 | 0.01% | |
| 5. | 89,215 | $435,369 | 0.23% |
News See All
Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings
Recursion Pharmaceuticals soared by 13.99 percent on Monday to close at $6.68 apiece as investors resorted to bargain-hunting following a two-day drop, while repositioning portfolios ahead of earnings...
Recursion Pharmaceuticals (RXRX) Extends Gains, Jumps 15.28% on Major AI Event
Recursion Pharmaceuticals extended its winning streak to a third straight day on Wednesday, jumping 15.28 percent to close at $6.79 apiece as investors loaded portfolios following a recently concluded...
Recursion Pharmaceuticals (RXRX) Climbs 16% Ahead of AI Conference
Next Wednesday, October 15, Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. (RXRX): A Bull Case Theory
We came across a bullish thesis on Recursion Pharmaceuticals, Inc. on Emil Hartela Investing’s Substack by Emil. In this article, we will summarize the bulls’ thesis on RXRX.
11 Best Penny Stocks with the Highest Upside Potential
On September 19, Morningstar released its research report on small-cap stocks as the sector started to rally. The small-cap stocks had largely underperformed the market for over a decade.
16 Stocks on Jim Cramer’s Radar Recently
On Thursday’s episode of Mad Money, host Jim Cramer, discussing the economy, described it as divided into two distinct tracks: one propelled by the rapid growth of artificial intelligence, and the other...
Recursion Pharmaceuticals, Inc. (RXRX) Secures $12.5M Milestone From Rallybio as REV102 Advances
Recursion Pharmaceuticals, Inc.
Top 10 AI-Powered Biotech Stocks to Buy Now
The head biotech analyst at Goldman Sachs, Salveen Richter, made an appearance on CNBC's "Squawk Box" on July 25 to discuss a variety of topics, including the status of the biotech industry and what to...
Needham Retains Buy Rating on Recursion Pharmaceuticals, Maintains PT at $8
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the 12 Best NASDAQ Penny Stocks to Buy According to Hedge Funds.
Hedge Fund Resource Center Billionaire Hedge Funds
